Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene Editing: Off-Target Effects Should Be A Key Safety Focus During Development, US FDA Says

Executive Summary

Clinical development programs for human gene therapy products that incorporate genome editing should address the potential risks of off-target editing as well as unintended consequences of on-target effects, agency says in new draft guidance.

You may also be interested in...



Gene/Cell Therapies: Sponsors Must Plan For Long-Term Safety Follow-Up Even If They Fold

In final guidance documents on development of CAR-T cell products and human genome therapies incorporating genome editing, US FDA says that sponsors should plan for continued follow-up, with funding, even if they cease operations or withdraw the IND.

Gene Editing: US Panel Review Of Vertex’s Exa-Cel To Focus On Nonclinical Assessment Of Off-Target Effects

Advisory committee discussion on the adequacy of Vertex’s analyses, using in silico and cellular methods, of off-target alterations with the gene therapy for sickle cell disease could help guide nonclinical assessment of future products made with CRISPR/Cas9-mediated gene editing.

Gene Therapy Development Should Involve Fewer Surprises, Says US FDA’s Marks

Regulators want to help smooth the process of bringing a gene therapy to market, hoping to iron out ‘surprises’ and even address reimbursement issues for the sake of patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel